Back to Search
Start Over
State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective
- Source :
- Am J Kidney Dis
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Phosphate binders are among the most common medications prescribed to patients with kidney failure receiving dialysis and are often used in advanced chronic kidney disease (CKD). In patients with CKD glomerular filtration rate category 3a (G3a) or worse, including those with kidney failure who are receiving dialysis, clinical practice guidelines suggest "lowering elevated phosphate levels towards the normal range" with possible strategies including dietary phosphate restriction or use of binders. Additionally, guidelines suggest restricting the use of oral elemental calcium often contained in phosphate binders. Nutrition guidelines in CKD suggest
- Subjects :
- medicine.medical_specialty
medicine.drug_class
medicine.medical_treatment
030232 urology & nephrology
Elemental calcium
Sevelamer
Article
Phosphates
03 medical and health sciences
Hyperphosphatemia
0302 clinical medicine
Renal Dialysis
medicine
Humans
030212 general & internal medicine
Renal Insufficiency, Chronic
Intensive care medicine
Dialysis
Chelating Agents
Clinical Trials as Topic
business.industry
medicine.disease
Patient Care Management
Phosphate binder
Lanthanum carbonate
Nephrology
Calcium
Hemodialysis
business
Kidney disease
medicine.drug
Subjects
Details
- ISSN :
- 02726386
- Volume :
- 77
- Database :
- OpenAIRE
- Journal :
- American Journal of Kidney Diseases
- Accession number :
- edsair.doi.dedup.....30e9a4721e3d6d4a6aef3644c4a44d9d
- Full Text :
- https://doi.org/10.1053/j.ajkd.2020.05.025